New Pancreatic Cancer Pill Daraxonrasib Doubles Survival Time in Historic Trial

When Dr. Brian Wolpin clicked to the survival data slide during the plenary session of the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, the packed auditorium erupted. Thousands of oncologists rose to their feet, delivering a rare, 42-second standing ovation. In the notoriously grueling field of pancreatic cancer research, breakthroughs of this magnitude are generational events.[2][5]

The applause was driven by the sheer desperation surrounding metastatic pancreatic ductal adenocarcinoma (mPDAC). The disease is one of the most aggressive and lethal malignancies in human biology. Because it is rarely detected early, most patients are diagnosed after the cancer has already spread to other organs. For these metastatic cases, the five-year relative survival rate hovers at a dismal 3 percent, and standard treatments have historically offered only marginal extensions of life.[1][2]

The standing ovation celebrated the arrival of daraxonrasib, a once-daily pill developed by the California-based biotech firm Revolution Medicines. The drug targets the KRAS mutation, a genetic error that acts as a broken "on" switch for cell growth. For decades, scientists knew that KRAS mutations drove the vast majority of pancreatic cancers, but the protein's smooth, featureless surface made it nearly impossible for drugs to bind to it, earning it the moniker of the "undruggable" target.[3][7]

The data presented at ASCO, and simultaneously published in the New England Journal of Medicine, detailed the results of the Phase 3 RASolute 302 clinical trial. The global study enrolled 500 patients with metastatic pancreatic cancer who had already received at least one prior line of treatment. Half were given standard-of-care intravenous chemotherapy, while the other half received the daily daraxonrasib pill.[1][4]

The headline figures represented a seismic shift in oncology. Patients receiving daraxonrasib achieved a median overall survival of 13.2 months, effectively doubling the 6.7-month median survival seen in the chemotherapy group. In the context of advanced pancreatic cancer, adding over half a year of life in a second-line setting is an unprecedented achievement.[2][6]

Beyond overall survival, the drug reduced the relative risk of death by 60 percent compared to chemotherapy. Progression-free survival—the amount of time patients lived without their tumors growing—also doubled, rising from 3.6 months in the chemotherapy arm to 7.2 months for those taking the targeted pill. Furthermore, one-third of the patients on daraxonrasib experienced substantial tumor shrinkage, compared to just 11.8 percent on chemotherapy.[2][6]

The success of daraxonrasib hinges on a novel mechanism of action. Rather than trying to wedge into a non-existent pocket on the KRAS protein, the drug acts as a "molecular glue." It binds the active, mutated RAS protein together with another abundant cellular protein called cyclophilin A. This forced pairing physically blocks the RAS protein from transmitting the signals that tell the cancer cells to multiply.[6][7]

Crucially, daraxonrasib is a "multi-selective" inhibitor. Early-generation KRAS drugs, which debuted a few years ago, only targeted a specific variant known as G12C. While effective for certain lung cancers, the G12C mutation is exceptionally rare in pancreatic cancer. Daraxonrasib, by contrast, shuts down the active state of multiple RAS variants, making it viable for the more than 90 percent of pancreatic cancer patients whose tumors are driven by the pathway.[1][7]

For patients and their families, the trial's quality-of-life data is just as vital as the survival metrics. Traditional chemotherapy for pancreatic cancer is notoriously toxic, often severely diminishing a patient's final months. Daraxonrasib, taken as a pill at home, spared patients from the systemic exhaustion of intravenous infusions and demonstrated a significantly more manageable safety profile.[3][4]

In the trial, 43.6 percent of patients on daraxonrasib experienced severe (Grade 3 or higher) adverse events, notably lower than the 57.5 percent rate seen in the chemotherapy group. Because of these side effects, only 1.2 percent of people in the daraxonrasib group had to stop treatment entirely, compared to 11.2 percent of those receiving chemotherapy.[1][2]

The nature of the side effects also differed fundamentally. While chemotherapy commonly caused severe fatigue, anemia, and dangerous drops in white blood cell counts, the primary side effects of daraxonrasib were rash, diarrhea, and mouth inflammation. Oncologists noted that while the rash can be severe and requires dermatological management, it is generally preferred over the systemic toxicity of traditional chemo.[1][2]

This improved tolerability translated directly into better patient-reported outcomes. The median time before patients experienced a significant increase in cancer-related pain was 9.2 months on daraxonrasib, compared to just 3.8 months on chemotherapy. Overall positive quality of life was preserved for more than twice as long, allowing patients to spend their extended time engaging in normal daily activities rather than recovering from treatment.[3][4]

The implications of the RASolute 302 trial extend far beyond a single disease. Dr. Rachna Shroff, an ASCO expert, declared to the press that "the RAS revolution is here." Because RAS mutations are the primary drivers in roughly 50 percent of colorectal cancers and 30 percent of non-small cell lung cancers, researchers are highly optimistic that daraxonrasib could soon rewrite the treatment protocols for those malignancies as well.[2][4]

Revolution Medicines is already moving aggressively to expand the drug's reach. The company is currently running global Phase 3 trials testing daraxonrasib in non-small cell lung cancer and colorectal cancer. Within pancreatic cancer, ongoing investigations are evaluating the drug as a first-line treatment, which could potentially allow newly diagnosed patients to bypass chemotherapy entirely.[4][7]

Recognizing the urgency of the data, the U.S. Food and Drug Administration (FDA) granted permission in early May 2026 for an expanded access program. This allows certain patients with previously treated metastatic pancreatic cancer to receive daraxonrasib before its official commercial launch. Revolution Medicines is now preparing to submit the full trial data to the FDA to secure formal regulatory approval.[6][7]

Despite the overwhelming optimism, researchers caution that daraxonrasib is not a cure. Like most targeted therapies, tumors eventually find evolutionary workarounds, developing resistance to the drug over time. Scientists are already studying these resistance mechanisms to identify combination therapies that could block the cancer's escape routes and extend survival even further.[1][2]

Nevertheless, the introduction of a highly effective, tolerable pill for one of medicine's most intractable diseases marks a historic milestone. For decades, a diagnosis of metastatic pancreatic cancer offered little hope and agonizingly short timelines. Today, the oncology community has proven that the disease's primary engine can be turned off, granting patients and their families the invaluable gift of time.[3][5]